Frank DeRosa
Overview
Explore the profile of Frank DeRosa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1560
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vaidya A, Parande D, Khadse N, Vargas-Montoya N, Agarwal V, Ortiz C, et al.
Anal Chem
. 2024 Mar;
96(14):5570-5579.
PMID: 38529613
Rational design and robust formulation processes are critical for optimal delivery of mRNA by lipid nanoparticles (LNPs). Varying degrees of heterogeneity in mRNA-LNPs can affect their biophysical and functional properties....
2.
Wang H, Ni X, Clark N, Randall K, Boeglin L, Chivukula S, et al.
Clin Proteomics
. 2024 Feb;
21(1):8.
PMID: 38311768
Background: Dynein axonemal intermediate chain 1 protein (DNAI1) plays an essential role in cilia structure and function, while its mutations lead to primary ciliary dyskinesia (PCD). Accurate quantitation of DNAI1...
3.
Sarode A, Patel P, Vargas-Montoya N, Allawzi A, Zhilin-Roth A, Karmakar S, et al.
Drug Deliv Transl Res
. 2023 Aug;
14(2):360-372.
PMID: 37526881
Pulmonary delivery of mRNA via inhalation is a very attractive approach for RNA-based therapy for treatment of lung diseases. In this work, we have demonstrated successful development of an mRNA-lipid...
4.
Goldman R, Turuvekere Vittala Murthy N, Northen T, Balakrishnan A, Chivukula S, Danz H, et al.
Biomaterials
. 2023 Jul;
301:122243.
PMID: 37480759
Lipid nanoparticles (LNPs) have shown great promise as delivery vehicles to transport messenger ribonucleic acid (mRNA) into cells and act as vaccines for infectious diseases including COVID-19 and influenza. The...
5.
Kalnin K, Plitnik T, Kishko M, Huang D, Raillard A, Piolat J, et al.
Vaccine
. 2022 Feb;
40(9):1289-1298.
PMID: 35101265
The emergence of SARS-CoV-2 variants, especially Beta and Delta, has raised concerns about the reduced protection from previous infection or vaccination based on the original Wuhan-Hu-1 (D614) virus. To identify...
6.
Chivukula S, Plitnik T, Tibbitts T, Karve S, Dias A, Zhang D, et al.
NPJ Vaccines
. 2021 Dec;
6(1):153.
PMID: 34916519
Recent approval of mRNA vaccines for emergency use against COVID-19 is likely to promote rapid development of mRNA-based vaccines targeting a wide range of infectious diseases. Compared to conventional approaches,...
7.
Kaczmarek J, Patel A, Rhym L, Capasso Palmiero U, Bhat B, Heartlein M, et al.
Biomaterials
. 2021 Jun;
275:120966.
PMID: 34147715
Non-viral vectors offer the potential to deliver nucleic acids including mRNA and DNA into cells in vivo. However, designing materials that effectively deliver to target organs and then to desired...
8.
Kalnin K, Plitnik T, Kishko M, Zhang J, Zhang D, Beauvais A, et al.
NPJ Vaccines
. 2021 Apr;
6(1):61.
PMID: 33875658
Emergency use authorization of COVID vaccines has brought hope to mitigate pandemic of coronavirus disease 2019 (COVID-19). However, there remains a need for additional effective vaccines to meet the global...
9.
Jackson N, Kester K, Casimiro D, Gurunathan S, DeRosa F
NPJ Vaccines
. 2020 Feb;
5:11.
PMID: 32047656
mRNA technologies have the potential to transform areas of medicine, including the prophylaxis of infectious diseases. The advantages for vaccines range from the acceleration of immunogen discovery to rapid response...
10.
Rybakova Y, Kowalski P, Huang Y, Gonzalez J, Heartlein M, DeRosa F, et al.
Mol Ther
. 2019 Jun;
27(8):1415-1423.
PMID: 31160223
Antibody-based drugs are a leading class of biologics used to treat a variety of diseases, including cancer. However, wide antibody implementation is hindered by manufacturing challenges and high production cost....